NVS News and Press, Novartis AG

2024-06-29 07:00:00 ET Summary The market remains near record highs with the best-ever presidential election year return and 13th-best S&P return through the first half of the year. Free cash flow yield is the best valuation metric since 1990, averaging 17.6% annual returns fo...

2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...

2024-06-22 07:00:00 ET Summary Stocks have been on fire since October lows, with many investors worried about bubbles and looming corrections. Even with the market at an all-time high, there are always extraordinary blue-chip bargains to buy. Optimal portfolio design with 11 s...

2024-06-20 04:02:15 ET More on MorphoSys, Novartis, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now MorphoSys: Hold Rating Until The Novartis Deal Closes Novartis, Roche facing...

2024-06-18 13:48:58 ET Summary Telix Pharmaceuticals' product revenues in full-year 2023 were $502.5 million, which was an increase of 214% from 2022 with revenues of only $160.1 million. TLX591 + best SOC is being used to treat patients with metastatic castration-resistant prosta...

2024-06-18 13:18:09 ET More on Celldex Celldex Therapeutics: Rising High, With Room For Further Growth Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celld...

2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...

2024-06-15 11:19:01 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Eli Lilly and Company (LLY) Goldman Sac...

2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...

2024-06-12 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although there was a time when the stock market was solely the playground of the wealthy, it no longer takes money to make money on Wall Street. The democratization of investing means even ...